Zai Lab Limited (ZLAB)
| Previous close | 14.22 |
| Open | 14.20 |
| Bid | 14.14 x 400 |
| Ask | 14.26 x 100 |
| Day's range | 13.93 - 14.22 |
| 52-week range | 13.48 - 39.50 |
| Volume | |
| Avg. volume | 681,124 |
| Market cap | 1.407B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.50 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.12 |
Business WireZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
SHANGHAI & CAMBRIDGE, Mass., April 15, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).
Business WireZai Lab Statement on Executive Management Team’s Agreement on Share Activities
SHANGHAI & CAMBRIDGE, Mass., April 11, 2024--The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of
Business WireZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
SHANGHAI & CAMBRIDGE, Mass., April 02, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.
